Patents by Inventor Yimin Qian

Yimin Qian has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20230263893
    Abstract: The present invention relates to bifunctional compounds, which find utility as modulators of targeted ubiquitination, especially inhibitors of a variety of polypeptides and other proteins which are degraded and/or otherwise inhibited by bifunctional compounds according to the present invention. In particular, the present invention is directed to compounds, which contain on one end a VHL ligand which binds to the ubiquitin ligase and on the other end a moiety which binds a target protein such that the target protein is placed in proximity to the ubiquitin ligase to effect degradation (and inhibition) of that protein. The present invention exhibits a broad range of pharmacological activities associated with compounds according to the present invention, consistent with the degradation/inhibition of targeted polypeptides.
    Type: Application
    Filed: November 2, 2022
    Publication date: August 24, 2023
    Inventors: Yimin QIAN, Hanqing DONG, Jing WANG, Michael BERLIN, Andrew P. CREW, Craig M. CREWS
  • Publication number: 20230232512
    Abstract: Provided is a control circuit, a control method and a lighting device compatible with a dimmer/switch. The dimmer/switch is connectable to a power supply input end of a light emitting module, and the control circuit includes a charging assistance module for assisting in charging of the dimmer/switch, that includes a first switch and a first resistor having a resistance value lower than a predetermined resistance value, so that when the first switch is turned on, an overall resistance value of the first resistor and the light emitting module is lower than the predetermined resistance value; and a charging control module, includes a constant voltage source and a second switch for controlling a voltage of a first control end of the first switch, so the first switch is turned on when an input voltage of the power supply input end is between 0 and a first predetermined voltage.
    Type: Application
    Filed: January 5, 2023
    Publication date: July 20, 2023
    Applicant: SAVANT TECHNOLOGIES LLC
    Inventors: Yimin ZHU, Chenyu HU, Xin QIAN, Aijun WANG
  • Publication number: 20230203030
    Abstract: The present invention relates to bifunctional compounds, which find utility as modulators of targeted ubiquitination, especially inhibitors of a variety of polypeptides and other proteins which are degraded and/or otherwise inhibited by bifunctional compounds according to the present invention. In particular, the present invention is directed to compounds, which contain on one end a VHL ligand which binds to the ubiquitin ligase and on the other end a moiety which binds a target protein such that the target protein is placed in proximity to the ubiquitin ligase to effect degradation (and inhibition) of that protein. The present invention exhibits a broad range of pharmacological activities associated with compounds according to the present invention, consistent with the degradation/inhibition of targeted polypeptides.
    Type: Application
    Filed: September 13, 2022
    Publication date: June 29, 2023
    Inventors: Andrew P. Crew, Craig M. Crews, Xin Chen, Hanqing Dong, Caterina Ferraro, Yimin Qian, Kam Siu, Jing Wang, Meizhong Jin, Michael Berlin, Kurt Zimmermann, Lawrence Snyder
  • Publication number: 20230183209
    Abstract: The description relates to cereblon E3 ligase binding compounds, including bifunctional compounds comprising the same, which find utility as modulators of targeted ubiquitination, especially inhibitors of a variety of polypeptides and other proteins which are degraded and/or otherwise inhibited by bifunctional compounds according to the present disclosure. In particular, the description provides compounds, which contain on one end a ligand which binds to the cereblon E3 ubiquitin ligase and on the other end a moiety which binds a target protein such that the target protein is placed in proximity to the ubiquitin ligase to effect degradation (and inhibition) of that protein. Compounds can be synthesized that exhibit a broad range of pharmacological activities consistent with the degradation/inhibition of targeted polypeptides of nearly any type.
    Type: Application
    Filed: December 12, 2022
    Publication date: June 15, 2023
    Applicant: Arvinas Operations, Inc.
    Inventors: Andrew P. CREW, Michael BERLIN, Keith R. HORNBERGER, Lawrence B. SNYDER, Jing WANG, Yimin QIAN, Hanqing DONG, Kurt ZIMMERMANN
  • Publication number: 20230150973
    Abstract: The present disclosure relates to novel compounds, pharmaceutical compositions containing such compounds, and their use in prevention and treatment of cancer and related diseases and conditions. In some embodiments, the compounds disclosed herein exhibit androgen receptor degradation activity.
    Type: Application
    Filed: June 27, 2022
    Publication date: May 18, 2023
    Applicant: ACCUTAR BIOTECHNOLOGY INC.
    Inventors: Jie FAN, Yimin QIAN, Wei HE, Ke LIU
  • Patent number: 11642342
    Abstract: Provided herein are pharmaceutical combinations, compositions, and methods of using a compound with estrogen receptor (ER) degradation activity, such as a compound of formula (I) or a tautomer, stereoisomer or a mixture of stereoisomers, or a pharmaceutically acceptable salt, or hydrate thereof, wherein R1, Y, R22, R33, R2, p, X3, X4, and Z are defined herein and a cyclin-dependent kinase (CDK) inhibitor.
    Type: Grant
    Filed: January 4, 2021
    Date of Patent: May 9, 2023
    Assignee: ACCUTAR BIOTECHNOLOGY
    Inventors: Jie Fan, Yimin Qian, Wei He
  • Publication number: 20230135173
    Abstract: The present disclosure relates to novel compounds, pharmaceutical compositions containing such compounds, and their use in prevention and treatment of cancer and related diseases and conditions. In some embodiments, the compounds disclosed herein exhibit androgen receptor degradation activity.
    Type: Application
    Filed: October 24, 2022
    Publication date: May 4, 2023
    Applicant: Accutar Biotechnology Inc.
    Inventors: Jie FAN, Yimin Qian, Wei He, Ke Liu
  • Publication number: 20230082997
    Abstract: The description relates to cereblon E3 ligase binding compounds, including bifunctional compounds comprising the same, which find utility as modulators of targeted ubiquitination, especially inhibitors of a variety of polypeptides and other proteins which are degraded and/or otherwise inhibited by bifunctional compounds according to the present disclosure. In particular, the description provides compounds, which contain on one end a ligand which binds to the cereblon E3 ubiquitin ligase and on the other end a moiety which binds a target protein such that the target protein is placed in proximity to the ubiquitin ligase to effect degradation (and inhibition) of that protein. Compounds can be synthesized that exhibit a broad range of pharmacological activities consistent with the degradation/inhibition of targeted polypeptides of nearly any type.
    Type: Application
    Filed: January 7, 2022
    Publication date: March 16, 2023
    Inventors: Michael BERLIN, Andrew P. CREW, Craig M. CREWS, Hanqing DONG, Keith R. HORNBERGER, Yimin QIAN, Lawrence B. SNYDER, Jing WANG, Kurt ZIMMERMANN
  • Patent number: 11597720
    Abstract: The present disclosure relates to bifunctional compounds, which find utility as modulators of estrogen receptor (target protein). In particular, the present disclosure is directed to bifunctional compounds, which contain on one end at least one of a Von Hippel-Lindau ligand, a cereblon ligand, inhibitors of apoptosis proteins ligand, mouse double-minute homolog 2 ligand, or a combination thereof, which binds to the respective E3 ubiquitin ligase, and on the other end a moiety which binds the target protein, such that the target protein is placed in proximity to the ubiquitin ligase to effect degradation (and inhibition) of target protein. The present disclosure exhibits a broad range of pharmacological activities associated with degradation/inhibition of target protein. Diseases or disorders that result from aggregation or accumulation of the target protein are treated or prevented with compounds and compositions of the present disclosure.
    Type: Grant
    Filed: July 17, 2020
    Date of Patent: March 7, 2023
    Assignee: Arvinas Operations, Inc.
    Inventors: Yimin Qian, Hanqing Dong, Jing Wang
  • Patent number: 11584743
    Abstract: The present disclosure relates to compounds and a pharmaceutically acceptable salt thereof, compositions, combinations and medicaments containing the compounds, and processes for their preparation. The disclosure also relates to the use of the compounds, combinations, compositions and medicaments, for example as inhibitors of the activity of the estrogen receptor, including degrading the estrogen receptor, the treatment of diseases and conditions mediated by the estrogen receptor.
    Type: Grant
    Filed: October 28, 2020
    Date of Patent: February 21, 2023
    Assignee: Arvinas Operations, Inc.
    Inventors: Andrew P. Crew, Yimin Qian, Hanging Dong, Jing Wang
  • Patent number: 11554171
    Abstract: The present invention relates to bifunctional compounds, which find utility as modulators of targeted ubiquitination, especially inhibitors of a variety of polypeptides and other proteins which are degraded and/or otherwise inhibited by bifunctional compounds according to the present invention. In particular, the present invention is directed to compounds, which contain on one end a VHL ligand which binds to the ubiquitin ligase and on the other end a moiety which binds a target protein such that the target protein is placed in proximity to the ubiquitin ligase to effect degradation (and inhibition) of that protein. The present invention exhibits a broad range of pharmacological activities associated with compounds according to the present invention, consistent with the degradation/inhibition of targeted polypeptides.
    Type: Grant
    Filed: June 25, 2020
    Date of Patent: January 17, 2023
    Assignees: Arvinas Operations, Inc., Yale University
    Inventors: Yimin Qian, Hanqing Dong, Jing Wang, Michael Berlin, Andrew P. Crew, Craig M. Crews
  • Patent number: 11535606
    Abstract: The present disclosure relates to novel compounds, pharmaceutical compositions containing such compounds, and their use in prevention and treatment of cancer and related diseases and conditions. In some embodiments, the compounds disclosed herein exhibit androgen receptor degradation activity.
    Type: Grant
    Filed: September 22, 2020
    Date of Patent: December 27, 2022
    Assignee: Accutar Biotechnology Inc.
    Inventors: Jie Fan, Yimin Qian, Wei He, Ke Liu
  • Patent number: 11530222
    Abstract: The present disclosure relates to novel compounds of Formula (I) that degrade Bruton's tyrosine kinase (BTK), pharmaceutical compositions containing such compounds, and their use in prevention and treatment of conditions modulated by BTK.
    Type: Grant
    Filed: February 2, 2022
    Date of Patent: December 20, 2022
    Assignee: Accutar Biotechnology Inc.
    Inventors: Yimin Qian, Wei He, Robert Luo, Jie Su, Hui Zhang, Ke Liu, Jie Fan
  • Publication number: 20220378726
    Abstract: The present disclosure relates to bifunctional compounds, which find utility as modulators of enhancer of zeste homolog 2 (target protein). In particular, the present disclosure is directed to bifunctional compounds, which contain on one end a Von Hippel-Lindau, cereblon, Inhibitors of Apotosis Proteins or mouse double-minute homolog 2 ligand which binds to the respective E3 ubiquitin ligase and on the other end a moiety which binds the target protein, such that the target protein is placed in proximity to the ubiquitin ligase to effect degradation (and inhibition) of target protein. The present disclosure exhibits a broad range of pharmacological activities associated with degradation/inhibition of target protein. Diseases or disorders that result from aggregation or accumulation of the target protein are treated or prevented with compounds and compositions of the present disclosure.
    Type: Application
    Filed: June 22, 2021
    Publication date: December 1, 2022
    Inventors: Andrew P. Crew, Lawrence B. Snyder, Jing Wang, Hanqing Dong, Yimin Qian, Michael Berlin
  • Patent number: 11512083
    Abstract: The present invention relates to bifunctional compounds, which find utility as modulators of targeted ubiquitination, especially inhibitors of a variety of polypeptides and other proteins which are degraded and/or otherwise inhibited by bifunctional compounds according to the present invention. In particular, the present invention is directed to compounds, which contain on one end a VHL ligand which binds to the ubiquitin ligase and on the other end a moiety which binds a target protein such that the target protein is placed in proximity to the ubiquitin ligase to effect degradation (and inhibition) of that protein. The present invention exhibits a broad range of pharmacological activities associated with compounds according to the present invention, consistent with the degradation/inhibition of targeted polypeptides.
    Type: Grant
    Filed: June 18, 2020
    Date of Patent: November 29, 2022
    Assignees: Arvinas Operations, Inc., Yale University
    Inventors: Andrew P. Crew, Craig M. Crews, Xin Chen, Hanqing Dong, Caterina Ferraro, Yimin Qian, Kam Siu, Jing Wang, Meizhong Jin, Michael Berlin, Kurt Zimmermann
  • Publication number: 20220274955
    Abstract: The present disclosure relates to bifunctional compounds, which find utility as modulators of estrogen receptor (target protein). In particular, the present disclosure is directed to bifunctional compounds, which contain on one end at least one of a Von Hippel-Lindau ligand, a cereblon ligand, inhibitors of apoptosis proteins ligand, mouse double-minute homolog 2 ligand, or a combination thereof, which binds to the respective E3 ubiquitin ligase, and on the other end a moiety which binds the target protein, such that the target protein is placed in proximity to the ubiquitin ligase to effect degradation (and inhibition) of target protein. The present disclosure exhibits a broad range of pharmacological activities associated with degradation/inhibition of target protein. Diseases or disorders that result from aggregation or accumulation of the target protein are treated or prevented with compounds and compositions of the present disclosure.
    Type: Application
    Filed: July 17, 2020
    Publication date: September 1, 2022
    Inventors: Andrew P. CREW, Yimin QIAN, Hanqing DONG, Jing WANG
  • Patent number: 11427548
    Abstract: The present disclosure relates to bifunctional compounds, which find utility to degrade (and inhibit) Androgen Receptor. In particular, the present invention is directed to compounds, which contain on one end a VHL ligand which binds to the ubiquitin ligase and on the other end a moiety which binds Androgen Receptor such that Androgen Receptor is placed in proximity to the ubiquitin ligase to effect degradation (and inhibition) of Androgen Receptor. The present invention exhibits a broad range of pharmacological activities associated with compounds according to the present invention, consistent with the degradation/inhibition of Androgen Receptor.
    Type: Grant
    Filed: October 17, 2019
    Date of Patent: August 30, 2022
    Assignee: ARVINAS OPERATIONS, INC.
    Inventors: Andrew P. Crew, Hanqing Dong, Jing Wang, Xin Chen, Yimin Qian, Kurt Zimmermann, Michael Berlin, Lawrence Snyder
  • Publication number: 20220267305
    Abstract: The present disclosure relates to bifunctional compounds, which find utility as modulators of estrogen receptor (target protein). In particular, the present disclosure is directed to bifunctional compounds, which contain on one end a cereblon, Von Hippel-Lindau ligase-binding moiety, Inhibitors of Apotosis Proteins, or mouse double-minute homolog 2 ligand, which binds to the respective E3 ubiquitin ligase, and on the other end a moiety which binds the target protein, such that the target protein is placed in proximity to the ubiquitin ligase to effect degradation (and inhibition) of target protein. The present disclosure exhibits a broad range of pharmacological activities associated with degradation/inhibition of target protein. Diseases or disorders that result from aggregation or accumulation of the target protein are treated or prevented with compounds and compositions of the present disclosure.
    Type: Application
    Filed: April 22, 2022
    Publication date: August 25, 2022
    Inventors: Andrew P. Crew, Hanqing Dong, Keith R. Hornberger, Yimin Qian, Jing Wang
  • Patent number: 11420956
    Abstract: The present disclosure relates to novel compounds, pharmaceutical compositions containing such compounds, and their use in prevention and treatment of cancer and related diseases and conditions. In some embodiments, the compounds disclosed herein exhibit androgen receptor degradation activity.
    Type: Grant
    Filed: September 22, 2020
    Date of Patent: August 23, 2022
    Assignee: Accutar Biotechnology Inc.
    Inventors: Jie Fan, Yimin Qian, Wei He, Ke Liu
  • Publication number: 20220259207
    Abstract: The present disclosure relates to novel compounds that degrade Bruton's tyrosine kinase (BTK), pharmaceutical compositions containing such compounds, and their use in prevention and treatment of conditions modulated by BTK.
    Type: Application
    Filed: February 2, 2022
    Publication date: August 18, 2022
    Applicant: ACCUTAR BIOTECHNOLOGY INC.
    Inventors: Yimin Qian, Wei He, Robert Luo, JIE SU, HUI ZHANG, KE LIU, JIE FAN